Discovery of benzhydrol-oxaborole derivatives as Streptococcus pneumoniae leucyl-tRNA synthetase inhibitors.

Bioorg Med Chem

State Key Laboratory of Microbial Metabolism, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, People's Republic of China. Electronic address:

Published: January 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Pneumonia caused by bacterium S. pneumoniae is a severe acute respiratory infectious disease with high morbidity and mortality, especially for children and immunity-compromised patients. The emergence of multidrug-resistant S. pneumoniae also presents a challenge to human health. Leucyl-tRNA synthetase (LeuRS) catalyzes the attachment of l-leucine to tRNA, which plays an essential role in protein translation and is considered an attractive antimicrobial drug target. In the present work, benzhydrol-oxaborole hybrid compounds were designed and synthesized as inhibitors of S. pneumoniae LeuRS. Exploration of the phenyl ring near Lysine 389 eventually yielded compounds 46 and 54 with submicromolar inhibitory potency. The co-crystal of compound 54 in the editing domain pocket of SpLeuRS was obtained and confirmed the formation of an additional hydrogen bond between the carbonyl of 54 and Lysine 389. It also showed anti-pneumococcal activity in vitro. The structure-activity relationship was discussed. This work will provide an essential foundation for the further development of anti-pneumococcal agents by targeting LeuRS.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2020.115871DOI Listing

Publication Analysis

Top Keywords

leucyl-trna synthetase
8
lysine 389
8
discovery benzhydrol-oxaborole
4
benzhydrol-oxaborole derivatives
4
derivatives streptococcus
4
pneumoniae
4
streptococcus pneumoniae
4
pneumoniae leucyl-trna
4
synthetase inhibitors
4
inhibitors pneumonia
4

Similar Publications

Antifungal activity of cinnamaldehyde against involves disruption of the TCA cycle and protein metabolism.

Front Microbiol

August 2025

Department of Medical Laboratory Diagnostics, School of Medical Technology, Shaoyang University, Shaoyang, China.

is an environmental opportunistic fungal pathogen, which can lead to invasive aspergillosis in immunocompromised individuals, and resistant to conventional antifungual agents has become a growing concern. This study investigated the antifungal activity and the molecular antifungal mechanisms of Cinnamaldehyde (CA) against , specifically its impact on metabolic pathways and protein metabolism. In susceptibility tests, CA was found to exhibit promising antifungal activity against in both solid and liquid culture (biomass) systems, with the minimum inhibitory concentration (MIC) determined as 40-80 μg/mL.

View Article and Find Full Text PDF

MitoQ alleviates m.3243A>G-induced mitochondrial dysfunction by stabilizing PINK1 and enhancing mitophagy.

J Genet Genomics

August 2025

Department of Endocrinology & Metabolism, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China. Electronic address:

The mitochondrial 3243A>G mutation (m.3243A>G) is associated with diverse clinical phenotypes. To elucidate the underlying mechanisms and explore intervention strategies in m.

View Article and Find Full Text PDF

Background: Phytopathogenic fungi pose a severe threat to global agriculture, and the emergence of drug-resistant strains underscores the urgent need for novel fungicides. Tavaborole (AN2690), a clinically approved benzoxaborole antifungal, suppresses fungal growth by selectively targeting leucyl-tRNA synthetase (LeuRS) through covalent binding-a unique mode of action. In this study, we designed and synthesized a series of novel tavaborole derivatives featuring substituted aniline moieties.

View Article and Find Full Text PDF

Introduction: Mitochondrial diseases caused by point mutations in mitochondrial tRNA (mt-tRNA) genes, including MELAS and MERRF syndromes, represent a significant unmet clinical need, due to the lack of effective treatments. We previously identified peptide molecules derived from human leucyl-tRNA synthetase, whose features make them attractive leads for the development of therapeutic agents against mt-tRNA point mutations-related diseases. Indeed, we demonstrated that, upon exogenous administration, these peptides penetrate human cell and mitochondrial membranes; stabilize mitochondrial tRNA structures; and rescue severe mitochondrial defects in cells bearing the point mutations m.

View Article and Find Full Text PDF

Diffuse large B-cell lymphoma (DLBCL) is a malignant tumor and research on its therapeutic targets has received increasing attention. It has been reported that Leucyl-tRNA synthetase (LARS) contributes to the growth and migration of non-Hodgkin lymphoma (NHL), yet its effect on DLBCL progression remains to be elucidated. MTT and flow cytometry were carried out to determine the cellular phenotypes of DLBCL cells under LARS overexpression.

View Article and Find Full Text PDF